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Despite immense efforts to combat malaria in tropical and sub-tropical regions, the potency of this
vector-borne disease and its status as a major driver of morbidity and mortality remain undisputed. We
develop an analytical pipeline for characterizing Plasmodium infection in a mouse model and identify
candidate urinary biomarkers that may present alternatives to immune-based diagnostic tools. We employ 1H
nuclear magnetic resonance (NMR) profiling followed by multivariate modeling to discover diagnostic
spectral regions. Identification of chemical structures is then made on the basis of statistical spectroscopy,
multinuclear NMR, and entrapment of candidates by iterative liquid chromatography (LC) and mass
spectrometry (MS). We identify two urinary metabolites (i) 4-amino-1-[3-hydroxy-5-(hydroxymethyl)-2,3-
dihydrofuran-2-yl]pyrimidin-2(1H)-one, (ii) 2-amino-4-({[5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-
4,5-dihydrofuran-2-yl]methyl}sulfanyl)butanoic acid that were detected only in Plasmodium berghei-infected
mice. These metabolites have not been described in the mammalian or parasite metabolism to date. This
analytical pipeline could be employed in prospecting for infection biomarkers in human populations.
P lasmodium falciparum is the most deadly human parasite, inflicting the greatest mortality and globalburden of all parasitic diseases1. In 2010, P. falciparum accounted for approximately 216 million clinicalcases and more than 600,000 deaths, mostly amongst children below the age of 5 years in sub-Saharan
Africa. Antigen-detecting rapid diagnostic tests (RDTs) for malaria have mushroomed in the last few years and
have undergone rigorous testing. The development and large-scale deployment of RDTs as point-of-care tests has
revolutionized malaria management. Clinical sensitivity, however, still leaves ground for improvement, particu-
larly in cases of low parasitemia2.
An additional complication is that in many tropical and sub-tropical regions, people are concurrently infected
with Plasmodium and parasitic worms (helminths), particularly in remote rural areas. One quarter of all school-aged
children on the African continent (,45 million) are likely to harbor concomitant infections with P. falciparum and
hookworm3, explained by the high degree of geographic overlap of the parasites. One obvious question is to what
extent a parasitic worm infection affects diagnosis, immune response, clinical manifestation, and prognosis of
malaria4,5.
Metabolic profiling has been used to gain knowledge about host-parasite interactions and to discover infection-
related metabolite patterns. Thus far, the majority of exploratory work has been conducted in rodent models
wherein each host-parasite model is represented by an infection-specific fingerprint in urine and/or plasma6–10.
Despite the widely assumed universality of eukaryotic metabolism, some class- or species-specific adaptions
exist in parasites, such as the trypanothione system in kinetoplasts (Leishmania spp. and Trypanosoma spp.) that
replaces glutathione-mediated detoxification of reactive oxygen species11. Compounds of exogenous origin
introduced into mammalian biofluids, represent ideal diagnostic biomarkers due to the specificity of the meta-
bolite. Given that a comprehensive humanmap ofmetabolism is still limited to date, and that between the human
metabolome database (HMDB) versions 2.0 and 3.0, the number of endogenous metabolites increased several-
fold12, it is realistic to assume that a significant pool of potential unexplored metabolic biomarkers exists, both in
the mammalian and in the parasitic system.
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In the present study, the malaria parasite P. berghei and the intest-
inal nematode Heligmosomoides bakeri, commonly utilized as a
model for hookworm infection13 are employed to establish murine
models of malaria with and without concurrent helminth infection.
An analytical pipeline is developed to structurally identify key
diagnostic metabolic components driving the urinary infection
signatures.
Results
Experimental setup and rationale. To investigate the metabolic
effects of a malaria-hookworm co-infection in the murine host in
a laboratory-controlled experiment, and to identify candidate
biomarkers that are predictive for P. berghei during single or co-
infection, we randomly divided mice into five groups, (i) single
infection with P. berghei (group P); (ii) single infection with
the mouse hookworm H. bakeri (group H); (iii) simultaneous co-
infection with both parasites (group SC); (iv) infection withH. bakeri
prior to infection with P. berghei (group DC); and (v) uninfected
(group Ctr) (Fig. 1). The experiment was run for 20 days in order
to establish a chronic helminth infection prior to malaria co-
infection. Groups H and DC were infected with H. bakeri on day 0
and groups P and DC were inoculated with P. berghei on day 15.
Group SCwas simultaneously infected with both parasites on day 15.
Plasma and urine samples were collected one day pre-infection and
five times during the course of infection up to day 19 post-infection.
Identification of candidate urinary biomarkers of P. berghei. Both
P. berghei and the co-infection groupsmanifest systematic changes in
the urinary metabolite profiles, as determined by orthogonal partial
least squares discriminant analysis (O-PLS-DA) of the NMR data.
Pipecolic acid and three initially unknown metabolites (UK1, UK2,
and UK3), are present in the P. berghei-infected groups (Table 1) on
day 16 (1 day postinfection with P. berghei). These four metabolites
are not detectable in the control group (Ctr) or in mice bearing a
single H. bakeri infection (H). The identity of pipecolic acid has
previously been confirmed by NMR by spiking of the reference
compound into urine from an infected animal9,14. Pipecolic acid is
a known component of urine but is typically not detected in NMR
urine profiles due to its low concentration.
UK1 andUK2 are structurally identified using ultra high perform-
ance liquid chromatography-time of flight-tandem mass spectro-
metry (UPLC-TOF-MS/MS) and liquid chromatography-NMR/
time of flight mass spectrometry (LC-NMR/TOF-MS). Accurate
MS, MS/MS, 1-dimensional (1D) and 2-dimensional (2D) NMR
experiments were conducted to elucidate the structure of UK2. The
MS/MS spectrum shows a neutral loss of cytosine (C4H5N3O) from
the parent ion atm/z 343.1083 corresponding to amolecular formula
C13H19N4O5S (Fig. S1). The resulting fragment with an m/z of
232.0645 corresponds to the even electron ion with the molecular
formula C9H14NO4S (didehydro ribose-homocysteine moiety). A
second fragmentation yields the cytosine cation with m/z 112.0531
after neutral loss of C9H13NO4S from the parent ion. The neutral loss
of the intact homocysteine moiety is not observed.
A heteronuclear correlation experiment, 1H-13C-HMBC, deter-
mines the connectivity of individual spin systems present in UK215.
Key correlations in the HSQC/HMBC overlay are provided in the
supplementary section (Fig. S1). The linkage of the cytosine and the
didehydro ribose moiety is confirmed by the HMBC cross peak
between H11/C8 at d1H 6.13 ppm and d13C 94 ppm (anomeric pro-
ton of the didehydro ribose moiety) and H3 at d1H 7.4 ppm (olefinic
proton of the cytosinemoiety at C5). The second correlation between
the –CH2 groups at H6/C12 (d13C 26.9 ppm) and H4/C13 (d13C
26.5 ppm) connect the didehydro ribose to the homocysteine moi-
ety. The chemical shifts and coupling pattern of UK1 are similar to
those of UK2, suggesting closely related molecular structures.
Detailed evidence for assignment is provided in the supplement
(Fig. S1). Based on the spectroscopic data the two unknown
metabolites are identified as (i) 4-amino-1-[3-hydroxy-5-(hydro-
xymethyl)-2,3-dihydrofuran-2-yl]pyrimidin-2(1H)-one (molecular
formula: C9H11N3O4; monoisotopic mass: 225.074956; chemical
shift: d 4.27(m), 4.96(t), 5.38(d), 6.17(d), 6.24(d), 7.60(d)) and (ii)
2-amino-4-({[5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-4,
5-dihydrofuran-2-yl]methyl}sulfanyl)butanoic acid (molecular
formula: C13H18N4O5S; monoisotopic mass: 342.37082; chemical
shift: d 2.07(m), 2.61(t), 3.35(q), 3.73(t), 4.88(t), 5.24(d), 5.93(d),
6.13(d), 7.40(d)). These two metabolites that are structurally iden-
tified from the combined NMR and MS information are likely to
be pathway related (Fig. 2). The metabolic profiling pipeline
developed to identify the two unknown potential diagnostic mar-
kers is depicted in Fig. S2.
The third unknown candidate biomarker for the P. berghei-
infected groups is associated with doublets at d1H 1.21 and d1H
1.24, which are statistically correlated but could not be cleanly iso-
lated. The compound does not ionize in themass spectrometer. Since
this compound only discriminates P. berghei infection at a single
timepoint, we did not pursue identification any further. Neither
pipecolic acid nor metabolites UK1 and UK2 vary significantly in
urinary concentration between mice with single and dual infection,
with the exception that urinary pipecolic acid levels are higher in the
day 19 simultaneous co-infection group (SC) than in the single P.
berghei infection group (P).
Figure 1 | Experimental design of the infectionmodels. Urine and plasma samples are collected from all mice (5 groups, n 5 8) one day before and 1, 8,
14, 16, and 19 days after the start of the experiment (day 0). The darker cells represent sampling days, the arrows represent infection timepoints.
P: P. berghei only; H: H. bakeri only; DC: delayed co-infection; SC: simultaneous co-infection; Ctr: uninfected control.
www.nature.com/scientificreports
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Comparison ofP. berghei single-infection with two hookworm co-
infection scenarios. The urine and plasma spectral profiles show
that all infection models specifically imprint on the host metabo-
lism (Tables 1, S1–S3). We show a typical 1H NMR urine spectrum
from (a) an uninfected control mouse (Ctr), (b) a P. berghei-infected
animal (P), and (c) a mouse that underwent delayed co-infection
(DC) at experimental day 19 (Fig. 3). In addition to the four
unique candidate urinary biomarkers of P. berghei, three of which
are consistently elevated across the single infection and both co-
infection groups (Table 1), changes in the concentrations of several
endogenous metabolites are apparent for P. berghei infection. In
brief, urine samples collected on day 16 show a number a relative
increase in acetate in mice simultaneously infected with P. berghei
and H. bakeri (group SC), compared to non-infected mice (Ctr
group) and an increase of 1-methylnicotinamide in the P. berghei-
infected group (P) compared to uninfected animals (Ctr). On day
19, concordant with increasing severity of infection, additional
changes such as an increase in creatine, 2-oxoisovalerate, and
2-oxoisocaproate are observed in the SC group in comparison with
either control group (Ctr or H). 2-Oxoisocaproate is also elevated in
the single P. berghei infection (P) over the delayed co-infection (DC),
whilst succinate is present in relatively lower concentrations in all P.
berghei-infected groups relative to controls.
The plasma profiles of animals infected with P. berghei show a
marked but changing response over the course of malaria infection
but do not yield any specific candidate biomarkers of Plasmodium
infection (Supplementary information, Tables S2, S3).
Parasite burden, body weight, and packed cell volume. Parasitemia
levels do not significantly differ in any of the pairwise comparisons
between the three P. berghei-infection groups. Levels of 39.5%
(69.4%), 35.3% (611.7%), and 37.1% (610.1%) are recorded for
the groups P, DC, and SC, respectively. Average worm counts of
42.4 (617.7) and 61.9 (618.4) correspond to groups H and DC,
respectively (p 5 0.053). The worm burden cannot be assessed in
the simultaneous co-infection, since H. bakeri larvae are too small
and embedded in the intestinal mucosa. No significant change in
body weight is observed between groups at any of the timepoints
assessed (detailed results are provided in Table S4). Packed cell
volume (PCV) values, on the other hand, are significantly lower in
group P compared to groupH (p5 0.012), and group SC (p5 0.019)
one day before infection (day21). However, this is no longer the case
on day 1 post-infection. There is no significant variation in mean
PCV values between the co-infection groups, or between P. berghei-
infected mice and each co-infection group. Infection with H. bakeri
alone does not lead to decreased PCV compared to group Ctr. The
mean PCV is lower in group P than in group DC (p 5 0.040) on day
16 only. Group P presents a significantly lower mean PCV value
(37.7%) compared to groups H or Ctr (52.6% and 51.9%, p 5
0.003 and 0.006, respectively) on day 19. Groups DC and SC
exhibit lower PCV values than the control groups (H and Ctr),
with mean PCV values of 28.5% and 34.3% (all p# 0.01) (Table S4).
Discussion
Candidate urinary biomarkers specific to P. berghei infection are
characterized from both single and hookworm co-infection models
of murine malaria. We find four discriminatory metabolites in the
urine of P. berghei-infected mice using a new analytical pipeline. We
deem three of these metabolites worthy for testing in human popula-
tions as candidate biomarkers for malaria: namely pipecolic acid, 4-
amino-1-[3-hydroxy-5-(hydroxymethyl)-2,3-dihydrofuran-2-yl]
pyrimidin-2(1H)-one (UK1), and its derivative 2-amino-4-({[5-
(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-4,5-dihydrofuran-2-
yl]methyl}sulfanyl)butanoic acid (UK2). These metabolites are
detected in P. berghei-infected groups (P, DC, and SC) but not in
control mice (Ctr) or animals withH. bakeri single-infection (H). We
are not able to conclusively identify the fourth metabolite (UK3),
which is part of the differential profile of all P. berghei infected groups
versus groups H and Ctr on day 16 post-infection. Of the three
structurally identified metabolites specific to P. berghei infection,
pipecolic acid has been reported previously and also unknown doub-
let signals at d 6.27 (UK1 and UK2) and d 1.20, 1.24 (UK3) associated
with P. berghei, were reported in the paper by Li et al. Pipecolic acid
was found to be positively discriminatory for rodent malaria from day
3 postinfection onwards9.
Pipecolic acid has been described in human P. vivax infections and
may hence represent a diagnostic biomarker for infection with
Plasmodium spp.16. In humans, accumulation of the compound
has been associated with a range of health conditions such as liver
dysfunction or neurological damage17–19, whereas pipecolic acid in
plants has been described as a key regulator of immunity to
microbes20. However, the role of pipecolic acid in Plasmodium infec-
tion remains elusive.
4-amino-1-[3-hydroxy-5-(hydroxymethyl)-2,3-dihydrofuran-2-
yl]pyrimidin-2(1H)-one, and 2-amino-4-({[5-(4-amino-2-oxopyr-
imidin-1(2H)-yl)-4-hydroxy-4,5-dihydrofuran-2-yl]methyl} sulfanyl)
butanoic acid are consistently detected in the urine of mice from all P.
berghei-infected groups, on days 16 and 19 and, to our knowledge,
neither of these metabolites has been observed before. They might
therefore be the most promising candidate biomarkers of P. berghei
infection. There is no significant difference between the single and co-
infected P. berghei groups in the level of excretion. These metabolites
are closely-related and share a common cytosine bound to didehydro
ribose as backbone structure. However, 2-amino-4-({[5-(4-amino-2-
oxopyrimidin-1(2H)-yl)-4-hydroxy-4,5-dihydrofuran-2-yl]methyl}
sulfanyl)butanoic acid carries an additional homocysteine.
The structural similarity between UK1 and UK2 suggests that
these compounds share a pathway-related relationship. Homocy-
steine, which is a constituent of UK2 has been reported to be found
in higher concentrations in the plasma in individuals with malaria or
Figure 2 | Chemical structure of UK1 and UK2. Molecular structure of
4-amino-1-[3-hydroxy-5-(hydroxymethyl)-2,3-dihydrofuran-2-
yl]pyrimidin-2(1H)-one (molecular formula: C9H11N3O4; monoisotopic
mass: 225.074956; chemical shift: 4.27(m), 4.96(t), 5.38(d), 6.17(d),
6.24(d), 7.60(d)) (a). Molecular structure of 2-amino-4-({[5-(4-amino-2-
oxopyrimidin-1(2H)-yl)-4-hydroxy-4,5-dihydrofuran-2-
yl]methyl}sulfanyl)butanoic acid (molecular formula: C13H18N4O5S;
monoisotopic mass: 342.37082; chemical shift: 2.07(m), 2.61(t), 3.35(q),
3.73(t), 4.88(t), 5.24(d), 5.93(d), 6.13(d), 7.40(d)) (b).
www.nature.com/scientificreports
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malnutrition21. The malaria parasite uses S-adenosyl-L-homocys-
teine (SAH) hydrolase to combat the toxicity of S-adenosyl-L-homo-
cysteine by converting SAH into adenosine and homocysteine22. Free
homocysteine is not observed in the NMR spectra of either urine or
plasma from P. berghei infected groups, although the resonancesmay
easily have been overshadowed by high concentration metabolites
from macromolecules, such as the lipoproteins, in the plasma.
Formation of UK1 is likely to be brought about by enzymatic
breakdown by an enzyme such as S-adenosyl-L-homocysteine
hydrolase or similar to remove the homocysteine moiety from
UK2. Since UK1 and UK2 have not previously been reported in
the literature, their molecular origin, their biological function and
subsequent metabolism is at this stage speculative. However, there is
a reasonable probability of N-acetylation on either of the amino
groups and this may influence the capacity of this molecule for
protein binding.
Several studies have reported an exacerbated response to malaria
following hookworm infection in humans, but we find that P. berghei
parasitemia, PCV, and body weight did not significantly vary in the
presence of H. bakeri, and neither did the absolute worm counts in
the presence of the P. berghei co-infection, which supports the find-
ing of de Souza et al. in C57Bl/6 mice23. A possible explanation for
this observation is that the murine intestinal nematode does not
induce anemia and, hence, is not representative of the stress imposed
by the hookworm in the human scenario24,25. However, although the
gross physiological measures suggest that no significant parasitologic
interaction took place, clear differences between the infection scen-
arios were identified in the urine and plasma composition, which
demonstrates that the complexity and specificity of host-parasite
interactions can still be reflected at the metabolic level without gross
differences in parasitemia.
The key outcome of this work is that the methodological frame-
work developed here for metabolic profiling-based biomarker dis-
covery, incorporating a sequential array of spectroscopic assays and
statistical spectroscopy, has genuine potential in parasite diagnostics.
Perhaps the application to parasitic infection is even more compel-
ling than in other disease scenarios because of the co-existence of
metabolites from both host and parasite. Here, two unique structur-
ally related urinary candidate biomarkers for murine malaria are
identified and, to our knowledge, have not been described so far in
Figure 3 | Typical 1H NMR-derived urine spectra. Representative sample obtained from an uninfected control mouse (a), mouse with P. berghei single
infection (b), and mouse with a delayed P. berghei-H. bakeri co-infection (c). The key to metabolite identity is the one indicated in Tables 1 and S5.
Additional abbreviations: ALA, alanine; CIT, citrate; CRT, creatinine; DMA, dimethylamine; 2OG, 2-oxoglutarate; TMAO, trimethylamine-N-oxide.
The water peak region was removed and the TMAO resonance truncated (as indicated by double bars) to allow vertical expansion.
www.nature.com/scientificreports
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the eukaryotic organism. We are furthermore able to confirm the
presence of previously described urinary pipecolic acid and a third
unknown (UK3) in P. berghei single and co-infections. Our work
presents here three candidate biomarkers (i.e. pipecolic acid, 4-
amino-1-[3-hydroxy-5-(hydroxymethyl)-2,3-dihydrofuran-2-yl]
pyrimidin-2(1H)-one and 2-amino-4-({[5-(4-amino-2-oxopyrimi-
din-1(2H)-yl)-4-hydroxy-4,5-dihydrofuran-2-yl]methyl}sulfanyl)
butanoic acid) to take forward for validation as early and specific
markers of plasmodium infection in human cohorts.
Methods
Sample origin. Details for the rodent model, infection parameters, and sampling
conditions are given in the supplementary information. In brief; the current work was
approved by the Swiss cantonal and national regulations of laboratory animal welfare
(permission no. 2081). Forty 3-week-old female NMRImice were split randomly into
5 groups P, H, SC, DC, and Ctr (n 5 8). Plasmodium infection in groups P, DC, and
SC was established with 2 3 107 erythrocytes, parasitized with the green fluorescent
protein (GFP)-transfected P. bergheiANKA strain in 0.2 ml red blood cell solution in
RPMI medium intravenously. Groups H, DC, and SC received 80 infective H. bakeri
third stage larvae (L3) which were administered orally in 150 ml water. Urine and
blood were collected from all mice one day before and after each infection timepoint
(1 day preinfection and days 1, 14, and 16), during the maturing helminth single
infection (day 8) and four days post P. berghei-infection (day 19).
Sample preparation and 1H nmr spectroscopic analysis. Urine samples were
prepared by mixing 30 ml phosphate buffer (43.8 mM NaH2PO4 and ,0.2 M
Na2HPO4, 70% D2O v/v, 0.1% sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4,
pH 5 7.4) with 30 ml urine.
The prepared samples were transferred into NMR microtubes (Bruker, diameter:
1.7 mm) shortly before measurement, and stored at 4uC prior to spectral acquisition.
A standard 1HNMR spectrumwas acquired from each individual sample on a Bruker
DRX 600 MHz spectrometer (Bruker Biospin, Rheinstetten, Germany), in a standard
1D experiment, using the standard solvent suppression pulse delay [recycle delay
(RD)-90u-tl-90u-tm-90u-acquire free induction decay (FID)]26. The relaxation delay
(RD) was typically 2 s long and tI at 3 ms, while the mixing time (tm) was set to
100 ms.Water irradiation was performed during the relaxation delay and also during
the mixing time. Acquisition time for each sample was 2.73 s and spectral width was
set to 20.017 p.p.m. A line broadening factor of 0.3 Hz was applied to the FID and the
FIDs were Fourier-transformed into spectra of 65.5 K points resolution. The samples
were scanned 256 times in each experiment at a constant temperature of 300 K.
Details for plasma preparation and analysis are given in the supplementary material.
Data reduction and multivariate analysis. All 1H NMR spectra were manually
phased and baseline-corrected in Topspin (version 3.1, Bruker), referenced to TSP at
d 0.00. The complete spectra were imported into MATLAB (version 7.12.0, R2011a)
and the water peak region was removed in all spectra (d 4.18–5.77). Further spectral
pre-processing included probabilistic quotient normalization and peak alignment,
using in-house developed scripts27.
O-PLS-DA was applied to compare 1H NMR spectral data between the different
murine infection groups and to identify the discriminating compounds (biomar-
kers)28,29. Assignment of unknowns was performed using MS and NMR data and the
CMC-se software (Bruker Biospin, Rheinstetten, Germany).
Validation of the candidate biomarkers.Candidate biomarkers identified inO-PLS-
DA (p, 0.05) were further validated by univariate analysis. The area under the curve
(AUC)was extracted from the clearest signal for eachmetabolite found significant via
O-PLS-DA analysis. Variance analysis between the mean values of the groups was
performed using a Mann-Whitney U test with Bonferroni correction, with a
significance cut-off level of 5%. Peaks that were found to be statistically insignificant
according to theMann-Whitney U test were removed unless they belonged to the top
five correlation coefficients extracted by multivariate (O-PLS-DA) analysis. All
identified peaks that showed significance in both analysis sets were documented
(Tables 1, S1–S3, and S5).
Identification of metabolic biomarkers. Metabolite identity was determined using
the literature9,26,30–33, statistical total correlation spectroscopy (STOCSY)29, and the
software Chenomx Profiler (Chenomx NMR Suite, 7.1, evaluation version).
The structural identity of the urinary metabolic discriminators UK1 and UK2 was
investigated by UPLC-TOF-MS/MS and LC-NMR/TOF-MS. The UPLC-MS results
were obtained on aWaters Acquity UPLC system (Milford, MA, USA) using a 100 3
2.1 mm 1.7 mm BEH C18 column at a flow rate of 0.25 ml/min. The mobile phase
consisted of acetonitrile 0.1% formic acid (B) and water 0.1% formic acid (A) with a
linear solvent gradient starting with 100% A, changing to 60% A after 12 min and to
0% A at 13 min. At 13.1 min, the composition was changed back to 100% A for re-
equilibration of the column. The injection volume was 5 mL. The chromatography
was coupled to a micrOTOF-Q mass spectrometer from Bruker Daltonic (Bremen,
Germany) operated in positive electrospray ionization mode with a scan range from
50 to 1000 m/z. MS/MS measurements were conducted at 22 eV with nitrogen as
collision gas after isolation of the precursor mass with m/z 343.
The LC-NMR/TOF-MS measurements were made on an Agilent 1260 HPLC
system (Waldbronn, Germany) coupled to a micrOTOF mass spectrometer (Bruker
Daltonic, Bremen Germany) and an AV III 600 MHz NMR spectrometer equipped
with a 5 mm BBO cryo probe (Bruker Biospin, Rheinstetten, Germany). A peak
sampling unit (BPSU-36, Bruker Biospin, Rheinstetten, Germany) was used to store
chromatographic peaks prior to transfer into a vial. The separation was achieved with
acetonitrile 0.1% formic acid (B) and deuteriumoxide 0.1% formic acid (A) on a 250
3 4.6 mm 5 mmAgilent Zorbax C18 column using a solvent gradient changing from
100% A to 90% A in 20 min. A total volume of 40 mL of pooled infected mouse urine
was injected on column. The peaks with m/z 231 (UK1, exchange of 4 protons with
deuterium) and 350 (UK2, exchange of 6 protons with deuterium) were stored from 3
(UK1) and 5 (UK2) individual injections in storage loops, transferred to a vial and
evaporated to dryness with a stream of nitrogen. The two compounds were re-
dissolved in 600 mL deuteriumoxide and measured in the cryo probe.
1D and 2DNMR experiments were conducted to elucidate the structure of UK2: A
1H-13C-HMBC was recorded with 1024 scans in 160 increments to determine the
connectivity of individual spin systems present in UK2. A 1H-13C-HSQC was
obtained for the detection of proton-carbon 1J-connectivities with 128 scans in 256
increments. Individual spin systems were identified from the 1H-1H-COSY acquired
with 16 scans in 256 increments. The structure of UK2 was calculated from the
molecular formula and the set of NMR data using the CMC-se software from Bruker
Biospin (Rheinstetten, Germany). Details for the assignment of the connectivity of
individual spin systems and the MS/MS spectrum for UK2 are provided in Fig. S1.
UK1 is structurally strongly related to UK2; in-depth structure elucidation was
therefore not necessary. LC-MS and LC-NMR/MS. Pooled urine samples were
injected on a 250 3 4.6 mm Kinetex C18 column with a particle diameter of 5 mm.
The separation was done on a 1200 series Agilent HPLC system consisting of a
quaternary HPLC pump, an auto sampler, a column oven and diode array detector.
Themobile phase consisted of D2O 0.1% formic acid (A) and acetonitrile 0.1% formic
acid (B). A linear gradient was applied from 100%A at 0 min to 95%A at 20 min. The
flow rate was 0.8 ml/min and the injection volume 50 ml. After chromatography, 2%
of the flow was split to a micrOTOF time-of-flight mass spectrometer (Bruker
Daltonics, Bremen, Germany) operated in positive ionization mode. Based on UV
andMS response, the peaks of interest were captured in the storage loops of a Bruker
Peak Sampling Unit (BPSU, Bruker Biospin, Rheinstetten, Germany). Ten injections
were collected and pooled in a vial and evaporated to dryness with a stream of
nitrogen gas. After re-constitution with D2O, all necessary experiments (1D-Proton,
COSY, HSQC and HMBC) were conducted to calculate the most probable structure
using the CMC-se software package (Complete Molecular Confidence-structure
elucidation software from Bruker Biospin, Rheinstetten, Germany). This software
picks the resonance peaks from the NMR data acquired and populates a correlation
table first. Together with the molecular formula obtained from the high resolution
mass spectrometry measurement the software then calculates possible structures
which are consistent with the signals in the correlation tables. Finally, the software
predicts the 13C chemical shift values for each possible structure and compares and
ranks this result with the real shifts. According to this, the most probable structures
for the unknown metabolites are shown in Fig. 2.
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